Skeletal benefits of soy isoflavones: A review of the clinical trial and epidemiologic data

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 7, Issue 6, 2004, Pages 649-658

  Messina, Mark ^a   Ho, Suzanne ^b   Alekel, D Lee ^c  

^a LOMA LINDA UNIVERSITY   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c IOWA STATE UNIVERSITY   (United States)

Author keywords

Clinical; Epidemiology; Isoflavones; Osteoporosis; Skeletal; Soy

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; HYDROXYPROLINE; ISOFLAVONE DERIVATIVE; OSTEOCALCIN; SOYBEAN PROTEIN;

BONE DENSITY; BONE TURNOVER; CALCANEUS; CLINICAL TRIAL; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; REVIEW; SKELETON; SOYBEAN;

AGE FACTORS; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH FOOD; HUMANS; ISOFLAVONES; OSTEOPOROSIS; POSTMENOPAUSE; SOYBEANS;

GLYCINE MAX;

EID: 14844282847     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200411000-00010     Document Type: Review

References (87)

1. Wasnich RD. Vertebral fracture epidemiology. Bone 1996; 18 (3 Suppl):179S-183S.
2. Melton LJ III. Epidemiology worldwide. Endocrinol Metab Clin North Am 2003; 32:1-13.
3. Melton LJ III. Epidemiology of hip fractures: implications of the exponential increase with age. Bone 1996; 18:121S-125S.
4. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670-676.
5. Fardellone P, Brazier M, Kamel S, et al. Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake. Am J Clin Nutr 1998; 67:1273-1278.
6. Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998; 129:81-88.
7. Chalmers J, Ho KC. Geographic variations in senile osteoporosis. The association with physical activity. J Bone Joint Surg Br 1970; 52:667-675.
8. Xu L, Lu A, Zhao X, et al. Very low rates of hip fracture in Beijing, People's Republic of China the Beijing Osteoporosis Project. Am J Epidemiol 1996; 144:901-907.
9. Gupta A. Osteoporosis in India: the nutritional hypothesis. Natl Med J India 1996; 9:268-274.
10. Mayr U, Butsch A, Schneider S. Validation of two in vitro test systems for estrogenic activities with zearalenone, phytoestrogens and cereal extracts. Toxicology 1992; 74:135-149.
11. Markiewicz L, Garey J, Adlercreutz H, Gurpide E. In vitro bioassays of nonsteroidal phytoestrogens. J Steroid Biochem Mol Biol 1993; 45:399-405.
12. de Aloysio D, Gambacciani M, Altieri P, et al. Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT. Gynecol Endocrinol 1997; 11:289-293.
13. Ross PD, Norimatsu H, Davis JW, et al. A comparison of hip fracture incidence among native Japanese, Japanese Americans, and American Caucasians. Am J Epidemiol 1991; 133:801-809.
14. Arjmandi BH, Alekel L, Mollis BW, et al. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr 1996; 126:161-167.
15. Potter SM, Baum JA, Teng H, et al. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998; 68:1375S-1379S.
16. Harrison E, Adjei A, Ameho C, et al. The effect of soybean protein on bone loss in a rat model of postmenopausal osteoporosis. J Nutr Sci Vitaminol (Tokyo) 1998; 44:257-268.
17. Arjmandi BH, Birnbaum R, Goyal NV, et al. Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr 1998; 68:1364S-1368S.
18. Arjmandi BH, Getlinger MJ, Goyal NV, et al. Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats. Am J Clin Nutr 1998; 68:1358S-1363S.
19. Blair HC, Jordan SE, Peterson TG, Barnes S. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J Cell Biochem 1996; 61:629-637.
20. Ishida H, Uesugi T, Hirai K, et al. Preventive effects of the plant isoflavones, daidzin and genistin, on bone loss in ovariectomized rats fed a calcium-deficient diet. Biol Pharm Bull 1998; 21:62-66.
21. Anderson JJ, Ambrose WW, Garner SC. Biphasic effects of genistein on bone tissue in the ovariectomized, lactating rat model. Proc Soc Exp Biol Med 1998; 217:345-350.
22. Fanti P, Monier-Faugere MC, Geng, Z, et al. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int 1998; 8:274-281.
23. Ishimi Y, Arai N, Wang X, et al. Difference in effective dosage of genistein on bone and uterus in ovariectomized mice. Biochem Biophys Res Commun 2000; 274:697-701.
24. Picherit C, Bennetau-Pelissero C, Chanteranne B, et al. Soybean isoflavones dose-dependently reduce bone turnover but do not reverse established osteopenia in adult ovariectomized rats. J Nutr 2001; 131:723-728.
25. Picherit C, Chanteranne B, Bennetau-Pelissero C, et al. Dose-dependent bone-sparing effects of dietary isoflavones in the ovariectomised rat. Br J Nutr 2001; 85:307-316.
26. Picherit C, Coxam V, Bennetau-Pelissero C, et al. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr 2000; 130:1675-1681.
27. Picherit C, Horcajada MN, Mathey J, et al. Isoflavone consumption does not increase the bone mass in osteopenic obese female zucker rats. Ann Nutr Metab 2003; 47:70-77.
28. Uesugi T, Toda T, Tsuji K, Ishida H. Comparative study on reduction of bone loss and lipid metabolism abnormality in ovariectomized rats by soy isoflavones, daidzin, genistin, and glycitin. Biol Pharm Bull 2001; 24:368-372.
29. Dalais FS, Rice GE, Wahlqvist ML, et al. Effects of dietary phytoestrogens in postmenopausal women. Climacteric 1998; 1:124-129.
30. Alekel DL, Germain AS, Peterson CT, et al. Isofiavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausai women. Am J Clin Nutr 2000; 72:844-852.
31. Hsu CS, Shen WW, Hsueh YM, Yeh SL. Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density. J Reprod Med 2001; 46:221-226.
32. Chen YM, Ho SC, Lam SS, et al. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 2003; 88:4740-4747. This relatively large 1-year trial that found high dose Isoflavone supplementation reduced bone loss at the hip but not spine in postmenopausal women when compared with the placebo and moderate-dose isoflavone groups.
33. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 2004; 292:65-74. This relatively large 1-year trial found that isoflavone-rich soy protein had no effect on bone mineral density at the hip or spine in older postmenopausal women.
34. Setchell KD, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr 2003; 78:593S-609S.
35. Branca F. Dietary phyto-oestrogens and bone health. Proc Nutr Soc 2003; 62:877-887.
36. rd ed. Madison: Crop Science Society of America and American Soybean Association; 2004. pp.1047-1117.
37. Murphy PA, Song T, Buseman G, et al. Isoflavones in retail and institutional soy foods. J Agric Food Chem 1999; 47:2697-2704.
38. Coward L, Smith M, Kirk M, Barnes S. Chemical modification of isoflavones in soyfoods during cooking and processing. Am J Clin Nutr 1998; 68:1486S-1491S.
39. Rowland I, Faughnan M, Hoey L, et al. Bioavailability of phyto-oestrogens. Br J Nutr 89 (Suppl 1):S45-S58.
40. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 2002; 132:3577-3584.
41. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138:863-870.
42. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139:4252-4263.
43. Teede HJ, Dalais FS, McGrath BP. Dietary soy containing phytoestrogens does not have detectable estrogenic effects on hepatic protein synthesis in postmenopausal women. Am J Clin Nutr 2004; 79:396-401. This short-term clinical trial showed that isoflavones did not affect serum concentrations of five proteins known to be affected by estrogen, thus demonstrating isoflavones and estrogens are not equivalent.
44. Brzezinski A, Adlercreutz H, Shaoul R, et al. Short-term effect of phytoestrogen-rich diet on postmenopausal women. Menopause 1997; 4:89-94.
45. An J, Tzagarakis-Foster C, Scharschmidt TC, et al. Estrogen receptor beta: selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 2001; 276:17808-17814.
46. Margeat E, Bourdoncle A, Margueron R, et al. Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta. J Mol Biol 2003; 326:77-92.
47. Kostelac D, Rechkemmer G, Briviba K. Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element. J Agric Food Chem 2003; 51:7632-7635.
48. Constantinou A, Huberman E. Genistein as an inducer of tumor cell differentiation: possible mechanisms of action. Proc Soc Exp Biol Med 1995; 208:109-115.
49. Nagata C, Takatsuka N, Kawakami N, Shimizu H. Soy product intake and premenopausal hysterectomy in a follow-up study of Japanese women. Eur J Clin Nutr 2001; 55:773-777.
50. Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 2001; 97:109-115.
51. Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. Menopause 2004; 11:290-298.
52. Fitzpatrick LA, Vincent A, Oberg A. Soy isoflavones increased bone turnover and lessened bone loss at the hip in postmenopausal women [abstract], J Bone Mineral Res 2003; 18:3161.
53. Morabito N, Crisafulli A, Vergara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 2002; 17:1904-1912. This one-year trial of postmenopausal women found that the soybean isoflavone genistein increased spinal and hip bone mineral density in postmenopausal women as effectively as conventional hormone therapy.
54. Chiechi L, Secreto G, D'Amore M, et al. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial. Maturitas 2002; 42:295.
55. Uesugi T, Fukui Y, Yamori Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: a four-week study. J Am Coll Nutr 2002; 21:97-102.
56. Uesugi T, Toda T, Okuhira T, Chen JT. Evidence of estrogenic effect by the three-month-intervention of isoflavone on vaginal maturation and bone metabolism in early postmenopausal women. Endocr J 2003; 50:613-619.
57. Yoles I, Yogev Y, Frenkel Y, et al. Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss. Menopause 2003; 10:522-525.
58. Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T. Soymilk or progesterone for prevention of bone loss. A 2 year randomized, placebo-controlled trial. Eur J Nutr 2004; 43:246-257.
59. Yamori Y, Moriguchi EH, Teramoto T, et al. Soybean isoflavones reduce postmenopausal bone resorption in female Japanese immigrants in Brazil: a ten-week study. J Am Coll Nutr 2002; 21:560-563.
60. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
61. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290:1729-1738.
62. Heaney RP. Calcium, dairy products and osteoporosis. J Am Coll Nutr 2000; 19:83S-99S.
63. Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001; 285:1482-1488.
64. Roughead ZK. Is the interaction between dietary protein and calcium destructive or constructive for bone? J Nutr 2003; 133:866S-869S.
65. Nomura A, Wasnich RD, Heilbrun LK, et al. Comparison of bone mineral content between Japan-born and US-born Japanese subjects in Hawaii, Bone Miner 1989; 6:213-223.
66. Ross PD, Fujiwara S, Huang C, et al. Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol 1995; 24:1171-1177.
67. Faulkner KG, McClung M, Cummings SR. Automated evaluation of hip axis length for predicting hip fracture. J Bone Miner Res 1994; 9:1065-1070.
68. Chin K, Evans MC, Cornish J, et al. Differences in hip axis and femoral neck length in premenopausal women of Polynesian, Asian and European origin. Osteoporos Int 1997; 7:344-347.
69. Yan L, Crabtree NJ, Reeve J, et al. Does hip strength analysis explain the lower incidence of hip fracture in the People's Republic of China? Bone 2004; 34:584-588.
70. Ho SC, Woo J, Chan SS, et al. Risk factors for falls in the Chinese elderly population. J Gerontol A Biol Sci Med Sci 1996; 51:M195-M198.
71. Aoyagi K, Ross PD, Davis JW, et al. Falls among community-dwelling elderly in Japan. J Bone Miner Res 1998; 13:1468-1474.
72. Davis JW, Ross PD, Nevitt MC, Wasnich RD. Incidence rates of falls among Japanese men and women living in Hawaii. J Clin Epidemiol 1997; 50:589-594.
73. Tsuchida K, Mizushima S, Toba M, Soda K. Dietary soybeans intake and bone mineral density among 995 middle-aged women in Yokohama. J Epidemiol 1999; 9:14-19.
74. Horiuchi T, Onouchi T, Takahashi M, et al. Effect of soy protein on bone metabolism in postmenopausal Japanese women. Osteoporos Int 2000; 11:721-724.
75. Nagata C, Shimizu H, Takami R, et al. Soy product intake and serum isoflavonoid and estradiol concentrations in relation to bone mineral density in postmenopausal Japanese women. Osteoporos Int 2002; 13:200-204.
76. Kimira M, Arai Y, Shimoi K, Watanabe S. Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol 1998; 8:168-175.
77. Katsuyama H, Ideguchi S, Fukunaga M, et al. Usual dietary intake of fermented soybeans (Natto) is associated with bone mineral density in premenopausal women. J Nutr Sci Vitaminol (Tokyo) 2002; 48:207-215.
78. Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 2001; 86:5217-5221.
79. Ho SC, Woo J, Lam S, et al. Soy protein consumption and bone mass in early postmenopausal Chinese women. Osteoporos Int 2003; 14:835-842.
80. Ho SC, Chan SG, Yi Q, et al. Soy intake and the maintenance of peak bone mass in Hong Kong Chinese women. J Bone Miner Res 2001; 16:1363-1369.
81. Kirn MK, Chung BC, Yu VY, et al. Relationships of urinary phyto-oestrogen excretion to BMD in postmenopausal women. Clin Endocrinol (Oxf) 2002; 56:321-328.
82. Kaneki M, Hedges SJ, Hosoi T, et al. Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk. Nutrition 2001; 17:315-321.
83. Simon JA, Mack CJ. Treatment of osteoporosis: combination therapies, Int J Fertil Womens Med 2003; 48:127-131; discussion 137-138.
84. Nestel P. Isoflavones: their effects on cardiovascular risk and functions. Curr Opin Lipidol 2003; 14:3-8.
85. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr 2003; 57:940-946.
86. Munro IC, Harwood M, Hlywka JJ, et al. Soy isoflavones: a safety review. Nutr Rev 2003; 61:1-33.
87. Unfer V, Casini ML, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004; 82:145-148.